2025 Q3 -tulosraportti
78 päivää sitten46 min
Tarjoustasot
Oslo Børs
Määrä
Osto
63
Myynti
Määrä
100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 63 | - | - | ||
| 85 | - | - | ||
| 10 | - | - | ||
| 158 | - | - |
Ylin
79,8VWAP
Alin
78,4VaihtoMäärä
2,5 32 074
VWAP
Ylin
79,8Alin
78,4VaihtoMäärä
2,5 32 074
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 19.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
5 t sitten5 t sittenProduct Overview Cevira (APL‑1702) is a drug–device photodynamic therapy (PDT) combination product designed as a non‑surgical, local treatment for: High‑grade squamous intraepithelial lesions (HSIL) of the cervix Including lesions caused by all HPV subtypes , with strong efficacy in HPV‑16 & HPV‑18 The system consists of: APL‑1702 ointment , applied directly to the cervix A single‑use light‑emitting device , which activates the drug after placement Patients can leave immediately after application; the device turns on/off automatically and is removed at home. Regulatory Status China (Primary Market Launch) NDA accepted: May 2024 Currently in the 2nd round of NMPA technical review Company has designated APL‑1702 as its top priority submission Multiple expert committees and guidelines are being updated to include the therapy United States December 2024: FDA feedback meeting completed Agreement reached on Phase III trial design for U.S. approval Company is seeking global partners for U.S. clinical development Market Need & Strategic Positioning Globally, no non‑surgical HSIL treatment has ever been approved APL‑1702 would be first‑in‑class Gynecologic experts emphasize: Rising HSIL incidence among younger women Need to avoid excisional surgery that harms fertility Expected to reshape cervical precancer treatment , offering: Fertility‑preserving Non‑invasive Clinic‑friendly therapy option China has: ~ 2.1 million HSIL patients ≥18 years 50% managed in tertiary hospitals , the primary target segment Commercialization Preparation The company is accelerating launch readiness: Presentations at top gynecologic congresses Public outreach around HPV and fertility‑preserving care Strategic partnerships (e.g., China Women’s Development Foundation, China Cancer Foundation) Building a full commercial team , focused on: Hospital penetration Multi‑channel access Physician education on photodynamic therapy Supply chain optimization to ensure immediate availability post‑approval Future Development Given strong Phase III results and high unmet need: Company has initiated exploration of an additional indication: HPV virus clearance independent of HSIL This could broaden Cevira’s market significantly.
·11 t sitten · MuokattuMassive volume of 25 m. Shares versus 7.6 m. Average over the last 3 months on Asieris last night. 7-8% up and it is at its highest level since May 2023. Something could indicate FOMO or data leak. My own personal favorite conspiracy theory is a data leak regarding positive APL 1702 approval. Waiting every day eagerly for a clarification - good luck to all 🫡🫡🥳🥳
·11 t sitten · Muokattu- ·2 päivää sittenPhotocure has broken out of an almost horizontal trend channel in the medium term after investors have steadily gone up in price to get in. A buy signal has been triggered and further upside for the stock is indicated. There is no resistance in the price chart and further upside is indicated. In case of reactions back, the stock has support at approximately 68.60 kroner. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated. The stock is considered technically positive overall in the medium term. Recommendation: buy
·2 päivää sitten · MuokattuPHOTOCURE: PHASE 3 STUDY SHOWS BENEFIT WITH HEXVIX IN BLADDER CANCER today 13-01-26 at 06:43 ∙ TDN Finans Oslo (Infront TDN Direkt): Photocure reports that new phase 3 data published in the journal Frontiers of Urology shows that blue light cystoscopy with Hexvix improves detection of bladder cancer compared to traditional white light when using modern HD equipment, according to a Monday announcement.
·3 päivää sittenHi, I've somewhat understood what's going on with this stock and a possible approval/contract. If this goes through, how much will it potentially rise by? And if it doesn't go through, will it fall a lot?
·2 päivää sittenYes, the USA takes time. Clearly. They "determine" what margins operations should deliver - to put it bluntly. One can choose to cut costs, operate at a minimum and only deliver products without investing for the future - or one can reinvest and plan for further expansion - as has been done with the liquidity surplus from product margins. They are, as is well known, sky-high.
·2 päivää sittenJust note that PHO has been working on this product since 2010. The result after 16 years is not impressive. But, if they *now* succeed with the operations, then that's good. So one can hope that the product is not challenged by future tech 🤞🏼
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
78 päivää sitten46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 5 t sitten5 t sittenProduct Overview Cevira (APL‑1702) is a drug–device photodynamic therapy (PDT) combination product designed as a non‑surgical, local treatment for: High‑grade squamous intraepithelial lesions (HSIL) of the cervix Including lesions caused by all HPV subtypes , with strong efficacy in HPV‑16 & HPV‑18 The system consists of: APL‑1702 ointment , applied directly to the cervix A single‑use light‑emitting device , which activates the drug after placement Patients can leave immediately after application; the device turns on/off automatically and is removed at home. Regulatory Status China (Primary Market Launch) NDA accepted: May 2024 Currently in the 2nd round of NMPA technical review Company has designated APL‑1702 as its top priority submission Multiple expert committees and guidelines are being updated to include the therapy United States December 2024: FDA feedback meeting completed Agreement reached on Phase III trial design for U.S. approval Company is seeking global partners for U.S. clinical development Market Need & Strategic Positioning Globally, no non‑surgical HSIL treatment has ever been approved APL‑1702 would be first‑in‑class Gynecologic experts emphasize: Rising HSIL incidence among younger women Need to avoid excisional surgery that harms fertility Expected to reshape cervical precancer treatment , offering: Fertility‑preserving Non‑invasive Clinic‑friendly therapy option China has: ~ 2.1 million HSIL patients ≥18 years 50% managed in tertiary hospitals , the primary target segment Commercialization Preparation The company is accelerating launch readiness: Presentations at top gynecologic congresses Public outreach around HPV and fertility‑preserving care Strategic partnerships (e.g., China Women’s Development Foundation, China Cancer Foundation) Building a full commercial team , focused on: Hospital penetration Multi‑channel access Physician education on photodynamic therapy Supply chain optimization to ensure immediate availability post‑approval Future Development Given strong Phase III results and high unmet need: Company has initiated exploration of an additional indication: HPV virus clearance independent of HSIL This could broaden Cevira’s market significantly.
- ·11 t sitten · MuokattuMassive volume of 25 m. Shares versus 7.6 m. Average over the last 3 months on Asieris last night. 7-8% up and it is at its highest level since May 2023. Something could indicate FOMO or data leak. My own personal favorite conspiracy theory is a data leak regarding positive APL 1702 approval. Waiting every day eagerly for a clarification - good luck to all 🫡🫡🥳🥳·11 t sitten · Muokattu
- ·2 päivää sittenPhotocure has broken out of an almost horizontal trend channel in the medium term after investors have steadily gone up in price to get in. A buy signal has been triggered and further upside for the stock is indicated. There is no resistance in the price chart and further upside is indicated. In case of reactions back, the stock has support at approximately 68.60 kroner. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated. The stock is considered technically positive overall in the medium term. Recommendation: buy
- ·2 päivää sitten · MuokattuPHOTOCURE: PHASE 3 STUDY SHOWS BENEFIT WITH HEXVIX IN BLADDER CANCER today 13-01-26 at 06:43 ∙ TDN Finans Oslo (Infront TDN Direkt): Photocure reports that new phase 3 data published in the journal Frontiers of Urology shows that blue light cystoscopy with Hexvix improves detection of bladder cancer compared to traditional white light when using modern HD equipment, according to a Monday announcement.
- ·3 päivää sittenHi, I've somewhat understood what's going on with this stock and a possible approval/contract. If this goes through, how much will it potentially rise by? And if it doesn't go through, will it fall a lot?·2 päivää sittenYes, the USA takes time. Clearly. They "determine" what margins operations should deliver - to put it bluntly. One can choose to cut costs, operate at a minimum and only deliver products without investing for the future - or one can reinvest and plan for further expansion - as has been done with the liquidity surplus from product margins. They are, as is well known, sky-high.·2 päivää sittenJust note that PHO has been working on this product since 2010. The result after 16 years is not impressive. But, if they *now* succeed with the operations, then that's good. So one can hope that the product is not challenged by future tech 🤞🏼
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
63
Myynti
Määrä
100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 63 | - | - | ||
| 85 | - | - | ||
| 10 | - | - | ||
| 158 | - | - |
Ylin
79,8VWAP
Alin
78,4VaihtoMäärä
2,5 32 074
VWAP
Ylin
79,8Alin
78,4VaihtoMäärä
2,5 32 074
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 19.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
2025 Q3 -tulosraportti
78 päivää sitten46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 19.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 5 t sitten5 t sittenProduct Overview Cevira (APL‑1702) is a drug–device photodynamic therapy (PDT) combination product designed as a non‑surgical, local treatment for: High‑grade squamous intraepithelial lesions (HSIL) of the cervix Including lesions caused by all HPV subtypes , with strong efficacy in HPV‑16 & HPV‑18 The system consists of: APL‑1702 ointment , applied directly to the cervix A single‑use light‑emitting device , which activates the drug after placement Patients can leave immediately after application; the device turns on/off automatically and is removed at home. Regulatory Status China (Primary Market Launch) NDA accepted: May 2024 Currently in the 2nd round of NMPA technical review Company has designated APL‑1702 as its top priority submission Multiple expert committees and guidelines are being updated to include the therapy United States December 2024: FDA feedback meeting completed Agreement reached on Phase III trial design for U.S. approval Company is seeking global partners for U.S. clinical development Market Need & Strategic Positioning Globally, no non‑surgical HSIL treatment has ever been approved APL‑1702 would be first‑in‑class Gynecologic experts emphasize: Rising HSIL incidence among younger women Need to avoid excisional surgery that harms fertility Expected to reshape cervical precancer treatment , offering: Fertility‑preserving Non‑invasive Clinic‑friendly therapy option China has: ~ 2.1 million HSIL patients ≥18 years 50% managed in tertiary hospitals , the primary target segment Commercialization Preparation The company is accelerating launch readiness: Presentations at top gynecologic congresses Public outreach around HPV and fertility‑preserving care Strategic partnerships (e.g., China Women’s Development Foundation, China Cancer Foundation) Building a full commercial team , focused on: Hospital penetration Multi‑channel access Physician education on photodynamic therapy Supply chain optimization to ensure immediate availability post‑approval Future Development Given strong Phase III results and high unmet need: Company has initiated exploration of an additional indication: HPV virus clearance independent of HSIL This could broaden Cevira’s market significantly.
- ·11 t sitten · MuokattuMassive volume of 25 m. Shares versus 7.6 m. Average over the last 3 months on Asieris last night. 7-8% up and it is at its highest level since May 2023. Something could indicate FOMO or data leak. My own personal favorite conspiracy theory is a data leak regarding positive APL 1702 approval. Waiting every day eagerly for a clarification - good luck to all 🫡🫡🥳🥳·11 t sitten · Muokattu
- ·2 päivää sittenPhotocure has broken out of an almost horizontal trend channel in the medium term after investors have steadily gone up in price to get in. A buy signal has been triggered and further upside for the stock is indicated. There is no resistance in the price chart and further upside is indicated. In case of reactions back, the stock has support at approximately 68.60 kroner. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated. The stock is considered technically positive overall in the medium term. Recommendation: buy
- ·2 päivää sitten · MuokattuPHOTOCURE: PHASE 3 STUDY SHOWS BENEFIT WITH HEXVIX IN BLADDER CANCER today 13-01-26 at 06:43 ∙ TDN Finans Oslo (Infront TDN Direkt): Photocure reports that new phase 3 data published in the journal Frontiers of Urology shows that blue light cystoscopy with Hexvix improves detection of bladder cancer compared to traditional white light when using modern HD equipment, according to a Monday announcement.
- ·3 päivää sittenHi, I've somewhat understood what's going on with this stock and a possible approval/contract. If this goes through, how much will it potentially rise by? And if it doesn't go through, will it fall a lot?·2 päivää sittenYes, the USA takes time. Clearly. They "determine" what margins operations should deliver - to put it bluntly. One can choose to cut costs, operate at a minimum and only deliver products without investing for the future - or one can reinvest and plan for further expansion - as has been done with the liquidity surplus from product margins. They are, as is well known, sky-high.·2 päivää sittenJust note that PHO has been working on this product since 2010. The result after 16 years is not impressive. But, if they *now* succeed with the operations, then that's good. So one can hope that the product is not challenged by future tech 🤞🏼
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
63
Myynti
Määrä
100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 63 | - | - | ||
| 85 | - | - | ||
| 10 | - | - | ||
| 158 | - | - |
Ylin
79,8VWAP
Alin
78,4VaihtoMäärä
2,5 32 074
VWAP
Ylin
79,8Alin
78,4VaihtoMäärä
2,5 32 074
Välittäjätilasto
Dataa ei löytynyt